Q-omics provides the consensus-scored CXCL3 profile across patient tissues and cancer cell-line models. CXCL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CXCL3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CXCL3 RNA expression shows 21,361 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where CXCL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL3 survival associations across molecular data types. CXCL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL3 RNA expression–survival associations across cancer types. High CXCL3 expression shows unfavorable associations in KIRC, CESC, UVM, THCA and LIHC, but favorable associations in COAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CXCL3 RNA expression.
This table summarizes CXCL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CXCL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL3 shows lower tumor expression in LUSC, LUAD, BRCA and KICH and higher tumor expression in COAD and ESCA. The COAD box plot shows higher CXCL3 RNA expression in tumor versus normal tissue (log2 FC = +2.856, t-test p < 0.001).
This table shows molecular features associated with CXCL3 in patient tissues and cancer cell lines. In patient samples, CXCL3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
